'Affordable' Russian Rituximab Biosimilar On Course In India

Biocad’s biosimilar rituximab appears headed for an Indian debut amid significant competition but the Russian firm appears confident that its “full-cycle production” will give it an edge and also facilitate a flexible pricing policy.